How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Items 101–200 of 1,000
Nowak-Sliwinska, P., Scapozza, L., & Ruiz i Altaba, A. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.005 · Cited by 183
How Chemoproteomics Can Enable Drug Discovery and Development
Moellering, R. E., & Cravatt, B. F. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.001 · Cited by 182
“Some of these pharmacologically driven discoveries led to ground-breaking medicines that are still used to treat human disorders today [6].”
BackgroundWhole-organism screening for gluconeogenesis identifies activators of fasting metabolism
Gut, P., Baeza-Raja, B., Andersson, O., Hasenkamp, L., Hsiao, J., Hesselson, D., Akassoglou, K., Verdin, E., Hirschey, M. D., & Stainier, D. Y. R. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1136 · Cited by 182
Identifying mechanism-of-action targets for drugs and probes
Gregori-Puigjané, E., Setola, V., Hert, J., Crews, B. A., Irwin, J. J., Lounkine, E., Marnett, L., Roth, B. L., & Shoichet, B. K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204524109 · Cited by 182
Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs
Wang, Y., Dix, M. M., Bianco, G., Remsberg, J. R., Lee, H.-Y., Kalocsay, M., Gygi, S. P., Forli, S., Vite, G., Lawrence, R. M., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0351-5 · Cited by 179
Booij, T. H., Price, L. S., & Danen, E. H. J. (2019) · SLAS Discovery · doi:10.1177/2472555219830087 · Cited by 176
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D2 Receptor Mechanism of Action
Dedic, N., Jones, P. G., Hopkins, S. C., Lew, R., Shao, L., Campbell, J. E., Spear, K. L., Large, T. H., Campbell, U. C., Hanania, T., et al. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.260281 · Cited by 176
Boyd, N. K., Teng, C., & Frei, C. R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.684515 · Cited by 197
Zebrafish Larvae Behavior Models as a Tool for Drug Screenings and Pre-Clinical Trials: A Review
Rosa, J. G. S., Lima, C., & Lopes-Ferreira, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126647 · Cited by 164
High-throughput organ-on-a-chip systems: Current status and remaining challenges
Probst, C., Schneider, S., & Loskill, P. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.02.004 · Cited by 171
Akbani, R., Becker, K.-F., Carragher, N., Goldstein, T., de Koning, L., Korf, U., Liotta, L., Mills, G. B., Nishizuka, S. S., Pawlak, M., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.o113.034918 · Cited by 170
Kell, D. B., & Goodacre, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.014 · Cited by 169
Accelerating reaction generality and mechanistic insight through additive mapping
Prieto Kullmer, C. N., Kautzky, J. A., Krska, S. W., Nowak, T., Dreher, S. D., & MacMillan, D. W. C. (2022) · Science · doi:10.1126/science.abn1885 · Cited by 167
Drug‐Target Residence Time—A Case for G Protein‐Coupled Receptors
Guo, D., Hillger, J. M., IJzerman, A. P., & Heitman, L. H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21307 · Cited by 166
Machine learning and image-based profiling in drug discovery
Scheeder, C., Heigwer, F., & Boutros, M. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.05.004 · Cited by 169
Applications in image-based profiling of perturbations
Caicedo, J. C., Singh, S., & Carpenter, A. E. (2016) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2016.04.003 · Cited by 168
Systems Pharmacology in Small Molecular Drug Discovery
Zhou, W., Wang, Y., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020246 · Cited by 162
Identifying compound efficacy targets in phenotypic drug discovery
Schirle, M., & Jenkins, J. L. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.08.001 · Cited by 164
Developments in preclinical cancer imaging: innovating the discovery of therapeutics
Conway, J. R. W., Carragher, N. O., & Timpson, P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3724 · Cited by 167
Systems-level antimicrobial drug and drug synergy discovery
Roemer, T., & Boone, C. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1205 · Cited by 159
Mateus, A., Määttä, T. A., & Savitski, M. M. (2016) · Proteome Science · doi:10.1186/s12953-017-0122-4 · Cited by 156
Bio-Inspired Nanomaterials for Micro/Nanodevices: A New Era in Biomedical Applications
Harun‐Ur‐Rashid, M., Jahan, I., Foyez, T., & Imran, A. B. (2023) · Micromachines · doi:10.3390/mi14091786 · Cited by 185
Recent advances in identifying protein targets in drug discovery
Ha, J., Park, H., Park, J., & Park, S. B. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.12.001 · Cited by 176
Major achievements of evidence-based traditional Chinese medicine in treating major diseases
Chao, J., Dai, Y., Verpoorte, R., Lam, W., Cheng, Y.-C., Pao, L.-H., Zhang, W., & Chen, S. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.06.123 · Cited by 158
Anticancer Effects of Niclosamide in Human Glioblastoma
Wieland, A., Trageser, D., Gogolok, S., Reinartz, R., Höfer, H., Keller, M., Leinhaas, A., Schelle, R., Normann, S., Klaas, L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2895 · Cited by 156
Target deconvolution techniques in modern phenotypic profiling
Lee, J., & Bogyo, M. S. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.12.022 · Cited by 184
Immunogenicity to Biologics: Mechanisms, Prediction and Reduction
Sethu, S., Govindappa, K., Alhaidari, M., Pirmohamed, M., Park, K., & Sathish, J. G. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0189-7 · Cited by 168
An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases
Brindha, J., Balamurali, M. M., & Chanda, K. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.622286 · Cited by 189
Data-driven medicinal chemistry in the era of big data
Lusher, S. J., McGuire, R., van Schaik, R. C., Nicholson, C. D., & de Vlieg, J. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.12.004 · Cited by 150
Koutsoukas, A., Lowe, R., KalantarMotamedi, Y., Mussa, H. Y., Klaffke, W., Mitchell, J. B. O., Glen, R. C., & Bender, A. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci300435j · Cited by 147
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease
Dale, T., Clarke, P. A., Esdar, C., Waalboer, D., Adeniji-Popoola, O., Ortiz-Ruiz, M.-J., Mallinger, A., Samant, R. S., Czodrowski, P., Musil, D., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1952 · Cited by 145
Niazi, S. K. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s424991 · Cited by 184
Senkowski, W., Zhang, X., Olofsson, M. H., Isacson, R., Höglund, U., Gustafsson, M., Nygren, P., Linder, S., Larsson, R., & Fryknäs, M. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0792 · Cited by 141
Chronic Stress-Induced Depression and Anxiety Priming Modulated by Gut-Brain-Axis Immunity
Westfall, S., Caracci, F., Estill, M., Frolinger, T., Shen, L., & Pasinetti, G. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670500 · Cited by 139
Löscher, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.730257 · Cited by 153
Is Target-Based Drug Discovery Efficient? Discovery and “Off-Target” Mechanisms of All Drugs
Sadri, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01737 · Cited by 162
Mathew, B., Parambi, D. G. T., Mathew, G. E., Uddin, M. S., Inasu, S. T., Kim, H., Marathakam, A., Unnikrishnan, M. K., & Carradori, S. (2019) · Archiv der Pharmazie · doi:10.1002/ardp.201900177 · Cited by 143
Artificial Intelligence in Pharmaceutical Sciences
Lu, M., Yin, J., Zhu, Q., Lin, G., Mou, M., Liu, F., Pan, Z., You, N., Lian, X., Li, F., et al. (2023) · Engineering · doi:10.1016/j.eng.2023.01.014 · Cited by 157
Dalecki, A. G., Crawford, C. L., & Wolschendorf, F. (2017) · Advances in microbial physiology/Advances in Microbial Physiology · doi:10.1016/bs.ampbs.2017.01.007 · Cited by 155
Christopher, J. A., Stadler, C., Martin, C. E., Morgenstern, M., Pan, Y., Betsinger, C. N., Rattray, D. G., Mahdessian, D., Gingras, A.-C., Warscheid, B., et al. (2021) · Nature Reviews Methods Primers · doi:10.1038/s43586-021-00029-y · Cited by 129
Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes
Dominguez, E., Galmozzi, A., Chang, J. W., Hsu, K.-L., Pawlak, J., Li, W., Godio, C., Thomas, J., Partida, D., Niessen, S., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1429 · Cited by 134
Global Phenotypic Screening for Antimalarials
Guiguemde, W. A., Shelat, A. A., Garcia-Bustos, J., Diagana, T. T., Gamo, F., & Guy, R. K. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.004 · Cited by 143
A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation
Lee, S., Nam, Y., Koo, J. Y., Lim, D., Park, J., Ock, J., Kim, J., Suk, K., & Park, S. B. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1669 · Cited by 139
Current Screening Methodologies in Drug Discovery for Selected Human Diseases
Lage, O. M., Ramos, M. C., Calisto, R., Almeida, E., Vasconcelos, V. M., & Vicente, F. (2018) · Marine Drugs · doi:10.3390/md16080279 · Cited by 157
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
Nygren, P., Fryknäs, M., Ågerup, B., & Larsson, R. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1539-5 · Cited by 133
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Chemoproteomics and Chemical Probes for Target Discovery
Drewes, G., & Knapp, S. (2018) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.06.008 · Cited by 132
Drug Discovery from Marine Microbes
Gerwick, W. H., & Fenner, A. M. (2012) · Microbial Ecology · doi:10.1007/s00248-012-0169-9 · Cited by 135
Synthesis of Complex and Diverse Compounds through Ring Distortion of Abietic Acid
Rafferty, R. J., Hicklin, R. W., Maloof, K. A., & Hergenrother, P. J. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201308743 · Cited by 133
Underexplored Opportunities for Natural Products in Drug Discovery
DeCorte, B. L. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00473 · Cited by 131
Using artificial intelligence methods to speed up drug discovery
Álvarez-Machancoses, Ó., & Fernández-Martínez, J. L. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1621284 · Cited by 124
Integrating Human Pluripotent Stem Cells into Drug Development
Engle, S. J., & Puppala, D. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.05.011 · Cited by 137
Neoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional Approaches
Lee, J. A., & Berg, E. L. (2013) · SLAS Discovery · doi:10.1177/1087057113506118 · Cited by 126
High-throughput imaging: Focusing in on drug discovery in 3D
Li, L., Zhou, Q., Voss, T. C., Quick, K. L., & LaBarbera, D. V. (2016) · Methods · doi:10.1016/j.ymeth.2015.11.013 · Cited by 128
Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics
Nixon, S. A., Welz, C., Woods, D. J., Costa, L. M., Zamanian, M., & Martin, R. J. (2020) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2020.07.001 · Cited by 150
How can attrition rates be reduced in cancer drug discovery?
Moreno, L., & Pearson, A. D. J. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.768984 · Cited by 143
Pizzorno, A., Padey, B., Terrier, O., & Rosa-Calatrava, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00531 · Cited by 122
“In that regard, many well-annotated collections of smallmolecule libraries could be readily made available through different collaborative and/or commercial partnerships in order to accelerate drug repurposing through hypothesis biased or unbiased phenotypic screening [reviewed in (54) (55) (56) (57) ].”
BackgroundEarly State Research on Antifungal Natural Products
Negri, M., Salci, T. P., Mesquita, C. S. S., Capoci, I. R. G., Svidzinski, T. I. E., & Kioshima, É. S. (2014) · Molecules · doi:10.3390/molecules19032925 · Cited by 147
Induced Pluripotent Stem Cells in Cardiovascular Drug Discovery
Mercola, M., Colas, A., & Willems, E. (2013) · Circulation Research · doi:10.1161/circresaha.111.250266 · Cited by 122
Predictive validity in drug discovery: what it is, why it matters and how to improve it
Scannell, J. W., Bosley, J., Hickman, J. A., Dawson, G. R., Truebel, H., Ferreira, G. S., Richards, D. B., & Treherne, J. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00552-x · Cited by 142
The Chemical Basis of Serine Palmitoyltransferase Inhibition by Myriocin
Wadsworth, J. M., Clarke, D. J., McMahon, S. A., Lowther, J., Beattie, A. E., Langridge‐Smith, P. R. R., Broughton, H. B., Dunn, T. M., Naismith, J. H., & Campopiano, D. J. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4059876 · Cited by 122
An Ancient Riboswitch Class in Bacteria Regulates Purine Biosynthesis and One-Carbon Metabolism
Kim, P. B., Nelson, J. W., & Breaker, R. R. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.01.001 · Cited by 129
The why and how of phenotypic small-molecule screens
Eggert, U. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1206 · Cited by 120
Kell, D. B. (2013) · The FEBS Journal · doi:10.1111/febs.12268 · Cited by 121
Cancer wars: natural products strike back
Basmadjian, C., Zhao, Q., Bentouhami, E., Djehal, A., Nebigil, C. G., Johnson, R. A., Serova, M., Gramont, A. D. E., Faivre, S. J., Raymond, É., et al. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00020 · Cited by 142
Cell Painting: a decade of discovery and innovation in cellular imaging
Seal, S., Trapotsi, M., Spjuth, O., Singh, S., Puigvert, J. C., Greene, N., Bender, A., & Carpenter, A. E. (2024) · Nature Methods · doi:10.1038/s41592-024-02528-8 · Cited by 155
Activity-based protein profiling: Recent advances in medicinal chemistry
Deng, H., Lei, Q., Wu, Y., He, Y., & Li, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112151 · Cited by 126
3D spheroid cultures improve the metabolic gene expression profiles of HepaRG cells
Takahashi, Y., Hori, Y., Yamamoto, T., Urashima, T., Ohara, Y., & Tanaka, H. (2015) · Bioscience Reports · doi:10.1042/bsr20150034 · Cited by 118
Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases
Chen, X., Barclay, J. W., Burgoyne, R. D., & Morgan, A. (2015) · Chemistry Central Journal · doi:10.1186/s13065-015-0143-y · Cited by 117
Fazly, A., Jain, C., Dehner, A. C., Issi, L., Lilly, E. A., Ali, A., Cao, H., Fidel, P. L., P. Rao, R., & Kaufman, P. D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305982110 · Cited by 112
Paveley, R. A., Mansour, N. R., Hallyburton, I., Bleicher, L. S., Benn, A. E., Mikic, I., Guidi, A., Gilbert, I. H., Hopkins, A. L., & Bickle, Q. D. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001762 · Cited by 117
NCATS launches drug repurposing program
Allison, M. (2012) · Nature Biotechnology · doi:10.1038/nbt0712-571a · Cited by 113
Whole-genome sequencing targets drug-resistant bacterial infections
Punina, N. V., Makridakis, N. M., Remnev, M. A., & Topunov, A. F. (2015) · Human Genomics · doi:10.1186/s40246-015-0037-z · Cited by 110
Image-based high-content screening in drug discovery
Lin, S., Schorpp, K., Rothenaigner, I., & Hadian, K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.06.001 · Cited by 124
Belema, M., & Meanwell, N. A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500335h · Cited by 124
Kambe, T., Correia, B. E., Niphakis, M. J., & Cravatt, B. F. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505517t · Cited by 113
The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods
Wagner, B. K., & Schreiber, S. L. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2015.11.008 · Cited by 111
Iskar, M., Zeller, G., Zhao, X., van Noort, V., & Bork, P. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.11.010 · Cited by 124
Why Are the Majority of Active Compounds in the CNS Domain Natural Products? A Critical Analysis
Bharate, S. S., Mignani, S., & Vishwakarma, R. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01922 · Cited by 102
Cisar, J. S., & Cravatt, B. F. (2012) · Journal of the American Chemical Society · doi:10.1021/ja304213w · Cited by 109
New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design
Ray, S., & Murkin, A. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00293 · Cited by 108
Antiprotozoal Activity Profiling of Approved Drugs: A Starting Point toward Drug Repositioning
Kaiser, M., Mäser, P., Tadoori, L. P., Ioset, J., & Brun, R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135556 · Cited by 111
Drug discovery and development for rare genetic disorders
Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107
“Despite this drawback, 28 NMEs were discovered and developed by phenotypic screenings between 1999 and 2008 (Swinney & Anthony, 2011).”
BackgroundNjoroge, M., Njuguna, N. M., Mutai, P., Ongarora, D. S. B., Smith, P. W., & Chibale, K. (2014) · Chemical Reviews · doi:10.1021/cr500098f · Cited by 111
The Valley of Death in anticancer drug development: a reassessment
Adams, D. J. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.02.001 · Cited by 106
Drug Discovery and Development
Sinha, S., & Vohora, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-802103-3.00002-x · Cited by 121
Ejalonibu, M. A., Ogundare, S. A., El-Rashedy, A. A. E., Ejalonibu, M. A., Lawal, M. M., Mhlongo, N. N., & Kumalo, H. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413259 · Cited by 121
Why is Research on Herbal Medicinal Products Important and How Can We Improve Its Quality?
Pelkonen, O., Xu, Q., & Fan, T.-P. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.124323 · Cited by 98
Discovery of Potent Broad Spectrum Antivirals Derived from Marine Actinobacteria
Raveh, A., Delekta, P. C., Dobry, C. J., Peng, W., Schultz, P. J., Blakely, P. K., Tai, A. W., Matainaho, T. K., Irani, D. N., Sherman, D. H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082318 · Cited by 118
Flannery, E. L., McNamara, C. W., Kim, S. W., Sakata, T., Li, F., Teng, C. H., Gagaring, K., Manary, M. J., Barboa, R., Meister, S., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500616x · Cited by 104
Yildirim, O., Gottwald, M., Schüler, P., & Michel, M. C. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00461 · Cited by 117
Recent advances in microfluidics for drug screening
Sun, J., Warden, A. R., & Ding, X. (2019) · Biomicrofluidics · doi:10.1063/1.5121200 · Cited by 115
Phase 0/microdosing approaches: time for mainstream application in drug development?
Burt, T., Young, G. C., Lee, W., Kusuhara, H., Langer, O., Rowland, M., & Sugiyama, Y. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0080-x · Cited by 119
Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening
Manjunatha, U. H., & Smith, P. W. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.031 · Cited by 111
Chemoproteomic approaches to drug target identification and drug profiling
Bantscheff, M., & Drewes, G. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.11.003 · Cited by 124
Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
Discovery and Development of Spleen Tyrosine Kinase (SYK) Inhibitors
Singh, R., Masuda, E. S., & Payan, D. G. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201271b · Cited by 106
Back to the Future with Phenotypic Screening
Prior, M., Chiruta, C., Currais, A. J. M., Goldberg, J., Ramsey, J., Dargusch, R., Maher, P. A., & Schubert, D. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500051h · Cited by 112
Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline
Cornet, C., Donato, V. D., & Terriente, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00703 · Cited by 117
Khan, S. M., & Witola, W. H. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1115522 · Cited by 121
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.